MARKET

AGEN

AGEN

Agenus
NASDAQ
7.05
+0.22
+3.22%
Opening 14:27 08/12 EDT
OPEN
6.91
PREV CLOSE
6.83
HIGH
7.20
LOW
6.83
VOLUME
663.70K
TURNOVER
--
52 WEEK HIGH
8.85
52 WEEK LOW
2.710
MARKET CAP
317.39M
P/E (TTM)
4.244
1D
5D
1M
3M
1Y
5Y
1D
Agenus Strengthens Board With New Director Appointment
TipRanks · 21h ago
Agenus Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on Agenus, Lowers Price Target to $25
Benzinga · 1d ago
Agenus price target lowered to $25 from $30 at H.C. Wainwright
TipRanks · 1d ago
Weekly Report: what happened at AGEN last week (0803-0807)?
Weekly Report · 2d ago
Agenus Inc. Reports No Material Changes to Previously Disclosed Risk Factors in Latest Review
TipRanks · 2d ago
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
NASDAQ · 4d ago
Agenus Offers Up To 77,976,718 Shares Of Common Stock By Selling Securityholders
Benzinga · 4d ago
More
About AGEN
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.

Webull offers Agenus Inc stock information, including NASDAQ: AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.